Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

3.

Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development.

Belyakov IM, Ahlers JD.

Curr Top Microbiol Immunol. 2012;354:157-79. doi: 10.1007/82_2010_119. Review.

PMID:
21203884
4.

Molecular pathways regulating CD4(+) T cell differentiation, anergy and memory with implications for vaccines.

Ahlers JD, Belyakov IM.

Trends Mol Med. 2010 Oct;16(10):478-91. doi: 10.1016/j.molmed.2010.07.007. Epub 2010 Aug 24. Review.

PMID:
20739220
5.

New paradigms for generating effective CD8+ T cell responses against HIV-1/AIDS.

Ahlers JD, Belyakov IM.

Discov Med. 2010 Jun;9(49):528-37.

6.

Lessons learned from natural infection: focusing on the design of protective T cell vaccines for HIV/AIDS.

Ahlers JD, Belyakov IM.

Trends Immunol. 2010 Mar;31(3):120-30. doi: 10.1016/j.it.2009.12.003. Epub 2010 Jan 19. Review.

PMID:
20089450
7.

What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?

Belyakov IM, Ahlers JD.

J Immunol. 2009 Dec 1;183(11):6883-92. doi: 10.4049/jimmunol.0901466. Review.

8.

Memories that last forever: strategies for optimizing vaccine T-cell memory.

Ahlers JD, Belyakov IM.

Blood. 2010 Mar 4;115(9):1678-89. doi: 10.1182/blood-2009-06-227546. Epub 2009 Nov 10. Review.

9.

Strategies for optimizing targeting and delivery of mucosal HIV vaccines.

Ahlers JD, Belyakov IM.

Eur J Immunol. 2009 Oct;39(10):2657-69. doi: 10.1002/eji.200939269. Review.

10.

Strategies for recruiting and targeting dendritic cells for optimizing HIV vaccines.

Ahlers JD, Belyakov IM.

Trends Mol Med. 2009 Jun;15(6):263-74. doi: 10.1016/j.molmed.2009.04.003. Epub 2009 May 30. Review.

PMID:
19487159
11.

Comment on "trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination".

Belyakov IM, Ahlers JD.

J Immunol. 2009 Feb 15;182(4):1779; author reply 1779-80. doi: 10.4049/jimmunol.0990002. No abstract available.

12.

Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine.

Belyakov IM, Ahlers JD.

Trends Immunol. 2008 Nov;29(11):574-85. doi: 10.1016/j.it.2008.07.010. Review.

PMID:
18838298
13.

Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization.

Belyakov IM, Ahlers JD, Nabel GJ, Moss B, Berzofsky JA.

Virology. 2008 Nov 10;381(1):106-15. doi: 10.1016/j.virol.2008.08.019. Epub 2008 Sep 14.

14.

Role of alpha3 domain of class I MHC molecules in the activation of high- and low-avidity CD8+ CTLs.

Belyakov IM, Kozlowski S, Mage M, Ahlers JD, Boyd LF, Margulies DH, Berzofsky JA.

Int Immunol. 2007 Dec;19(12):1413-20. Epub 2007 Nov 1.

PMID:
17981793
15.

Progress on new vaccine strategies against chronic viral infections.

Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, Terabe M, Belyakov IM.

J Clin Invest. 2004 Aug;114(4):450-62. Review.

16.

Mucosal AIDS vaccines: current status and future directions.

Belyakov IM, Ahlers JD, Berzofsky JA.

Expert Rev Vaccines. 2004 Aug;3(4 Suppl):S65-73. Review.

PMID:
15285706
17.

Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, Morris JC.

J Clin Invest. 2004 Jun;113(11):1515-25. Review.

18.

Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells.

Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA.

J Clin Invest. 2004 Apr;113(7):998-1007.

19.

Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS, Snyder JT, Ahlers JD, Franchini G, Moss B, Berzofsky JA.

Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9458-63. Epub 2003 Jul 17.

20.

Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines.

Ahlers JD, Belyakov IM, Berzofsky JA.

Curr Mol Med. 2003 May;3(3):285-301. Review.

PMID:
12699364
21.

Selective induction of high avidity CTL by altering the balance of signals from APC.

Oh S, Hodge JW, Ahlers JD, Burke DS, Schlom J, Berzofsky JA.

J Immunol. 2003 Mar 1;170(5):2523-30.

22.

A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L.

Ahlers JD, Belyakov IM, Terabe M, Koka R, Donaldson DD, Thomas EK, Berzofsky JA.

Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13020-5. Epub 2002 Sep 13.

23.

Assessing CD4+ helper T-lymphocyte responses by lymphoproliferation.

Quakyi IA, Ahlers JD.

Methods Mol Med. 2002;72:369-83. No abstract available.

PMID:
12125133
24.

Strategies for designing and optimizing new generation vaccines.

Berzofsky JA, Ahlers JD, Belyakov IM.

Nat Rev Immunol. 2001 Dec;1(3):209-19. Review.

PMID:
11905830
25.

Activating CTL precursors to reveal CTL function without skewing the repertoire by in vitro expansion.

Belyakov IM, Wang J, Koka R, Ahlers JD, Snyder JT, Tse R, Cox J, Gibbs JS, Margulies DH, Berzofsky JA.

Eur J Immunol. 2001 Dec;31(12):3557-66.

26.
27.

Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques.

Belyakov IM, Hel Z, Kelsall B, Kuznetsov VA, Ahlers JD, Nacsa J, Watkins DI, Allen TM, Sette A, Altman J, Woodward R, Markham PD, Clements JD, Franchini G, Strober W, Berzofsky JA.

Nat Med. 2001 Dec;7(12):1320-6.

PMID:
11726972
28.
29.

Mechanisms of cytokine synergy essential for vaccine protection against viral challenge.

Ahlers JD, Belyakov IM, Matsui S, Berzofsky JA.

Int Immunol. 2001 Jul;13(7):897-908.

PMID:
11431420
30.

Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific CTL.

Belyakov IM, Ahlers JD, Clements JD, Strober W, Berzofsky JA.

J Immunol. 2000 Dec 1;165(11):6454-62.

31.

Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections.

Berzofsky JA, Ahlers JD, Derby MA, Pendleton CD, Arichi T, Belyakov IM.

Immunol Rev. 1999 Aug;170:151-72. Review.

PMID:
10566149
32.

A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL.

Matsui S, Ahlers JD, Vortmeyer AO, Terabe M, Tsukui T, Carbone DP, Liotta LA, Berzofsky JA.

J Immunol. 1999 Jul 1;163(1):184-93.

33.
34.
35.

Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge.

Belyakov IM, Derby MA, Ahlers JD, Kelsall BL, Earl P, Moss B, Strober W, Berzofsky JA.

Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1709-14.

36.

Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence.

Ahlers JD, Takeshita T, Pendleton CD, Berzofsky JA.

Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10856-61.

38.
39.

Synthetic peptides from P. falciparum sexual stage 25-kDa protein induce antibodies that react with the native protein: the role of IL-2 and conformational structure on immunogenicity of Pfs25.

Quakyi IA, Miller LH, Good MF, Ahlers JD, Isaacs SN, Nunberg JH, Houghten RA, Keister DB, Coligan JE, Moss B, et al.

Pept Res. 1995 Nov-Dec;8(6):335-44.

PMID:
8838417
40.

Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule.

Takeshita T, Takahashi H, Kozlowski S, Ahlers JD, Pendleton CD, Moore RL, Nakagawa Y, Yokomuro K, Fox BS, Margulies DH, et al.

J Immunol. 1995 Feb 15;154(4):1973-86.

PMID:
7530749

Supplemental Content

Loading ...
Support Center